Table 1.
Participants’ Baseline Characteristics
|
Placebo group
|
VD3 group
|
p-value | ||||
|---|---|---|---|---|---|---|
| Frequency | Percent | Frequency | Percent | |||
| Gender* | Male | 12 | 60.0 | 16 | 80.0 | 0.168 |
| Female | 8 | 40.0 | 4 | 20.0 | ||
| AERD | Yes | 3 | 15.0 | 3 | 15.0 | 1.000 |
| No | 17 | 85.0 | 17 | 85.0 | ||
| Revision Surgery |
Yes | 2 | 10.0 | 2 | 10.0 | 1.000 |
| No | 18 | 90.0 | 18 | 90.0 | ||
| Age (year)** | Placebo group | VD3 group | P-value (diff CI) | |||
| mean | SD | mean | SD | |||
| 42.05 | 13.79 | 41.35 | 13.58 | 0.87 (-8.06-9.46) | ||
| VIT.D level in blood*** | 17.81 | 4.64 | 17.61 | 4.49 | 0.89 (-2.67-3.06) | |
| Pre op SNOT-22 score# | 67.05 | 17.44 | 63.4 | 19.45 | 0.53(-8.17-15.47) | |
| Pre op Meltzer score## | 3.75 | 0.55 | 3.40 | 0.75 | 0.16 (-0.07-0.77) | |
*Chi2: 1.90, df:1, **t: 0.162, df:38, ***t:0.138, df:38,# t:0.625, df:38,##t: 1.67, df:38 AERD: aspirin-exacerbated respiratory disease